Recombinant Antibody Production Service - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509241584

Publication Date:

September 5, 2024

Pages:

129

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for Recombinant Antibody Production Service was estimated to be worth US$ 814 million in 2023 and is forecast to a readjusted size of US$ 1195.3 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030
North American market for Recombinant Antibody Production Service was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Antibody Production Service was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Recombinant Antibody Production Service was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Recombinant Antibody Production Service include evitria SA, Bon Opus Biosciences, Biomatik, Biointron Biological Inc., Sino Biological, ProSci Inc, GenScript, RayBiotech and Cygnus Technologies, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Antibody Production Service, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Recombinant Antibody Production Service by region & country, by Type, and by Application.
The Recombinant Antibody Production Service market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Antibody Production Service.
麻豆原创 Segmentation
By Company
evitria SA
Bon Opus Biosciences
Biomatik
Biointron Biological Inc.
Sino Biological
ProSci Inc
GenScript
RayBiotech
Cygnus Technologies
Cusabio Technology
Absolute Antibody
Cayman Chemical
Creative Biolabs
Promab Biotechnologies
Leinco Technologies
R&D Systems
Rapid Novor
ACROBiosystems
Segment by Type:
High-throughput Antibody Production Service
Small to Mid-scale Antibody Production Service
Large-scale Antibody Production Service
Chimeric Antibody Production Service
Antibody Fragment Production Service
Bispecific Antibody Production Service
Others
Segment by Application
Pharmaceutical
Biotechnology Company
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Antibody Production Service manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Recombinant Antibody Production Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Recombinant Antibody Production Service in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Recombinant Antibody Production Service Product Introduction
1.2 Global Recombinant Antibody Production Service 麻豆原创 Size Forecast
1.3 Recombinant Antibody Production Service 麻豆原创 Trends & Drivers
1.3.1 Recombinant Antibody Production Service Industry Trends
1.3.2 Recombinant Antibody Production Service 麻豆原创 Drivers & Opportunity
1.3.3 Recombinant Antibody Production Service 麻豆原创 Challenges
1.3.4 Recombinant Antibody Production Service 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Antibody Production Service Players Revenue Ranking (2023)
2.2 Global Recombinant Antibody Production Service Revenue by Company (2019-2024)
2.3 Key Companies Recombinant Antibody Production Service Manufacturing Base Distribution and Headquarters
2.4 Key Companies Recombinant Antibody Production Service Product Offered
2.5 Key Companies Time to Begin Mass Production of Recombinant Antibody Production Service
2.6 Recombinant Antibody Production Service 麻豆原创 Competitive Analysis
2.6.1 Recombinant Antibody Production Service 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Recombinant Antibody Production Service Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Antibody Production Service as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 High-throughput Antibody Production Service
3.1.2 Small to Mid-scale Antibody Production Service
3.1.3 Large-scale Antibody Production Service
3.1.4 Chimeric Antibody Production Service
3.1.5 Antibody Fragment Production Service
3.1.6 Bispecific Antibody Production Service
3.1.7 Others
3.2 Global Recombinant Antibody Production Service Sales Value by Type
3.2.1 Global Recombinant Antibody Production Service Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Antibody Production Service Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Antibody Production Service Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical
4.1.2 Biotechnology Company
4.1.3 Others
4.2 Global Recombinant Antibody Production Service Sales Value by Application
4.2.1 Global Recombinant Antibody Production Service Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Antibody Production Service Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Antibody Production Service Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Antibody Production Service Sales Value by Region
5.1.1 Global Recombinant Antibody Production Service Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Antibody Production Service Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Antibody Production Service Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Antibody Production Service Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Recombinant Antibody Production Service Sales Value, 2019-2030
5.2.2 North America Recombinant Antibody Production Service Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Recombinant Antibody Production Service Sales Value, 2019-2030
5.3.2 Europe Recombinant Antibody Production Service Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Recombinant Antibody Production Service Sales Value, 2019-2030
5.4.2 Asia Pacific Recombinant Antibody Production Service Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Recombinant Antibody Production Service Sales Value, 2019-2030
5.5.2 South America Recombinant Antibody Production Service Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Recombinant Antibody Production Service Sales Value, 2019-2030
5.6.2 Middle East & Africa Recombinant Antibody Production Service Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Antibody Production Service Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Antibody Production Service Sales Value
6.3 United States
6.3.1 United States Recombinant Antibody Production Service Sales Value, 2019-2030
6.3.2 United States Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Antibody Production Service Sales Value, 2019-2030
6.4.2 Europe Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Antibody Production Service Sales Value, 2019-2030
6.5.2 China Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Antibody Production Service Sales Value, 2019-2030
6.6.2 Japan Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Antibody Production Service Sales Value, 2019-2030
6.7.2 South Korea Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Antibody Production Service Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Antibody Production Service Sales Value, 2019-2030
6.9.2 India Recombinant Antibody Production Service Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Antibody Production Service Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 evitria SA
7.1.1 evitria SA Profile
7.1.2 evitria SA Main Business
7.1.3 evitria SA Recombinant Antibody Production Service Products, Services and Solutions
7.1.4 evitria SA Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.1.5 evitria SA Recent Developments
7.2 Bon Opus Biosciences
7.2.1 Bon Opus Biosciences Profile
7.2.2 Bon Opus Biosciences Main Business
7.2.3 Bon Opus Biosciences Recombinant Antibody Production Service Products, Services and Solutions
7.2.4 Bon Opus Biosciences Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.2.5 Bon Opus Biosciences Recent Developments
7.3 Biomatik
7.3.1 Biomatik Profile
7.3.2 Biomatik Main Business
7.3.3 Biomatik Recombinant Antibody Production Service Products, Services and Solutions
7.3.4 Biomatik Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.3.5 Biointron Biological Inc. Recent Developments
7.4 Biointron Biological Inc.
7.4.1 Biointron Biological Inc. Profile
7.4.2 Biointron Biological Inc. Main Business
7.4.3 Biointron Biological Inc. Recombinant Antibody Production Service Products, Services and Solutions
7.4.4 Biointron Biological Inc. Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.4.5 Biointron Biological Inc. Recent Developments
7.5 Sino Biological
7.5.1 Sino Biological Profile
7.5.2 Sino Biological Main Business
7.5.3 Sino Biological Recombinant Antibody Production Service Products, Services and Solutions
7.5.4 Sino Biological Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.5.5 Sino Biological Recent Developments
7.6 ProSci Inc
7.6.1 ProSci Inc Profile
7.6.2 ProSci Inc Main Business
7.6.3 ProSci Inc Recombinant Antibody Production Service Products, Services and Solutions
7.6.4 ProSci Inc Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.6.5 ProSci Inc Recent Developments
7.7 GenScript
7.7.1 GenScript Profile
7.7.2 GenScript Main Business
7.7.3 GenScript Recombinant Antibody Production Service Products, Services and Solutions
7.7.4 GenScript Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.7.5 GenScript Recent Developments
7.8 RayBiotech
7.8.1 RayBiotech Profile
7.8.2 RayBiotech Main Business
7.8.3 RayBiotech Recombinant Antibody Production Service Products, Services and Solutions
7.8.4 RayBiotech Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.8.5 RayBiotech Recent Developments
7.9 Cygnus Technologies
7.9.1 Cygnus Technologies Profile
7.9.2 Cygnus Technologies Main Business
7.9.3 Cygnus Technologies Recombinant Antibody Production Service Products, Services and Solutions
7.9.4 Cygnus Technologies Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.9.5 Cygnus Technologies Recent Developments
7.10 Cusabio Technology
7.10.1 Cusabio Technology Profile
7.10.2 Cusabio Technology Main Business
7.10.3 Cusabio Technology Recombinant Antibody Production Service Products, Services and Solutions
7.10.4 Cusabio Technology Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.10.5 Cusabio Technology Recent Developments
7.11 Absolute Antibody
7.11.1 Absolute Antibody Profile
7.11.2 Absolute Antibody Main Business
7.11.3 Absolute Antibody Recombinant Antibody Production Service Products, Services and Solutions
7.11.4 Absolute Antibody Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.11.5 Absolute Antibody Recent Developments
7.12 Cayman Chemical
7.12.1 Cayman Chemical Profile
7.12.2 Cayman Chemical Main Business
7.12.3 Cayman Chemical Recombinant Antibody Production Service Products, Services and Solutions
7.12.4 Cayman Chemical Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.12.5 Cayman Chemical Recent Developments
7.13 Creative Biolabs
7.13.1 Creative Biolabs Profile
7.13.2 Creative Biolabs Main Business
7.13.3 Creative Biolabs Recombinant Antibody Production Service Products, Services and Solutions
7.13.4 Creative Biolabs Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.13.5 Creative Biolabs Recent Developments
7.14 Promab Biotechnologies
7.14.1 Promab Biotechnologies Profile
7.14.2 Promab Biotechnologies Main Business
7.14.3 Promab Biotechnologies Recombinant Antibody Production Service Products, Services and Solutions
7.14.4 Promab Biotechnologies Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.14.5 Promab Biotechnologies Recent Developments
7.15 Leinco Technologies
7.15.1 Leinco Technologies Profile
7.15.2 Leinco Technologies Main Business
7.15.3 Leinco Technologies Recombinant Antibody Production Service Products, Services and Solutions
7.15.4 Leinco Technologies Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.15.5 Leinco Technologies Recent Developments
7.16 R&D Systems
7.16.1 R&D Systems Profile
7.16.2 R&D Systems Main Business
7.16.3 R&D Systems Recombinant Antibody Production Service Products, Services and Solutions
7.16.4 R&D Systems Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.16.5 R&D Systems Recent Developments
7.17 Rapid Novor
7.17.1 Rapid Novor Profile
7.17.2 Rapid Novor Main Business
7.17.3 Rapid Novor Recombinant Antibody Production Service Products, Services and Solutions
7.17.4 Rapid Novor Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.17.5 Rapid Novor Recent Developments
7.18 ACROBiosystems
7.18.1 ACROBiosystems Profile
7.18.2 ACROBiosystems Main Business
7.18.3 ACROBiosystems Recombinant Antibody Production Service Products, Services and Solutions
7.18.4 ACROBiosystems Recombinant Antibody Production Service Revenue (US$ Million) & (2019-2024)
7.18.5 ACROBiosystems Recent Developments
8 Industry Chain Analysis
8.1 Recombinant Antibody Production Service Industrial Chain
8.2 Recombinant Antibody Production Service Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Antibody Production Service Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Antibody Production Service Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

evitria SA
Bon Opus Biosciences
Biomatik
Biointron Biological Inc.
Sino Biological
ProSci Inc
GenScript
RayBiotech
Cygnus Technologies
Cusabio Technology
Absolute Antibody
Cayman Chemical
Creative Biolabs
Promab Biotechnologies
Leinco Technologies
R&D Systems
Rapid Novor
ACROBiosystems

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.